PR Newswire BiotechnologyQwen · 实盘不做把握 0/10不做原因:不是事件🔁 +1 同一事件
北京时间·🕒 发布 21:12:00·⟳ 抓取 21:12:26 +26s·⚡ 决策 08-27 21:13:22 +56s·61.4 天前
QuidelOrtho发布Science Bytes播客第60期，回顾2026年ADLM年会诊断技术演讲
该信号是一期企业播客节目的发布，内容为此前行业会议演讲的回顾与讨论，不包含新产品发布、财务数据、监管批准、订单或任何可交易的增量信息。这属于常规企业公关/教育内容，不构成可交易事件。
📄 原文PR Newswire Biotechnology↗ 原文
Faster Answers, Better Decisions: ADLM 2026 Highlights
SAN DIEGO, Aug. 27, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnosti…
不做 QuidelOrtho Corporation（QDEL.US）
该事件为企业播客节目发布，内容为行业会议演讲回顾，不含任何新增产品、订单、监管、财务或指引信息，不构成可交易催化，无方向性edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
QuidelOrtho发布Science Bytes播客第60期，回顾2026年ADLM年会三场演讲（快速分子诊断、PCT抗生素管理、高敏肌钙蛋白）。全文无任何新增产品、合同、监管、财务或指引信息，仅为已有技术的科普性讨论。播客发布不构成股价催化，方向中性，无可交易edge。
🔎 新鲜度:最早出现 2026-08-27 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:播客发布类事件在历史先例中无可比样本，因为此类事件本身不构成股价催化
方向:无先例可参考
涨幅量级:无
形态:无
原文全文
展开原文 · 2,923 字
SAN DIEGO, Aug. 27, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 60 of its Science Bytes podcast, featuring highlights from the 2026 Association for Diagnostics and Laboratory Medicine (ADLM) Annual Conference.
Hosted by Stephanie Kleewein, the special episode showcases three presentations addressing some of healthcare's most pressing challenges: delivering faster molecular diagnostic results, improving antibiotic stewardship and accelerating cardiovascular assessment.
Featured guests include Dr. Heather Danks, Chief Technology Officer at LEX Diagnostics; Dr. Mike Broyles, Director of Medical Affairs for Biomarkers at Thermo Fisher Scientific; and Dr. Lindy Carlstrom, Medical Affairs Manager at QuidelOrtho. Together, they discuss how innovation is helping clinicians gain faster, more actionable insights when time matters most.
Key Insights:
- Ultra-fast RT-PCR technology can deliver respiratory test results in as little as six minutes and complete results in less than 10 minutes
- Simplified workflows are helping expand molecular testing into near-patient and CLIA-waived settings
- Procalcitonin (PCT) provides clinicians with a reliable biomarker to support antibiotic stewardship and reduce unnecessary antibiotic use
- Real-world PCT implementation has been associated with reductions in antibiotic exposure, readmissions and adverse events
- High-sensitivity troponin testing enables faster assessment of patients presenting with suspected cardiac events
- Advances in diagnostic precision are helping emergency departments improve patient flow and support timely clinical decisions
Across molecular diagnostics, infectious disease management and cardiovascular care, the conversation highlights a common goal: providing clinicians with rapid, actionable information that supports confident decision-making and better patient outcomes.
Listen to the latest episode of the QuidelOrtho Science Bytes podcast on major streaming platforms or at https://www.quidelortho.com/global/en/resources/podcasts/quidelortho-science-bytes.
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
[email protected]
Media Contact:
Stephanie Kleewein
Senior Corporate Communication and PR Manager
[email protected]
SOURCE QuidelOrtho Corporation
Hosted by Stephanie Kleewein, the special episode showcases three presentations addressing some of healthcare's most pressing challenges: delivering faster molecular diagnostic results, improving antibiotic stewardship and accelerating cardiovascular assessment.
Featured guests include Dr. Heather Danks, Chief Technology Officer at LEX Diagnostics; Dr. Mike Broyles, Director of Medical Affairs for Biomarkers at Thermo Fisher Scientific; and Dr. Lindy Carlstrom, Medical Affairs Manager at QuidelOrtho. Together, they discuss how innovation is helping clinicians gain faster, more actionable insights when time matters most.
Key Insights:
- Ultra-fast RT-PCR technology can deliver respiratory test results in as little as six minutes and complete results in less than 10 minutes
- Simplified workflows are helping expand molecular testing into near-patient and CLIA-waived settings
- Procalcitonin (PCT) provides clinicians with a reliable biomarker to support antibiotic stewardship and reduce unnecessary antibiotic use
- Real-world PCT implementation has been associated with reductions in antibiotic exposure, readmissions and adverse events
- High-sensitivity troponin testing enables faster assessment of patients presenting with suspected cardiac events
- Advances in diagnostic precision are helping emergency departments improve patient flow and support timely clinical decisions
Across molecular diagnostics, infectious disease management and cardiovascular care, the conversation highlights a common goal: providing clinicians with rapid, actionable information that supports confident decision-making and better patient outcomes.
Listen to the latest episode of the QuidelOrtho Science Bytes podcast on major streaming platforms or at https://www.quidelortho.com/global/en/resources/podcasts/quidelortho-science-bytes.
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
[email protected]
Media Contact:
Stephanie Kleewein
Senior Corporate Communication and PR Manager
[email protected]
SOURCE QuidelOrtho Corporation
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。